Redmond Asset Management LLC Sells 88 Shares of Becton, Dickinson and Company (NYSE:BDX)

Redmond Asset Management LLC decreased its position in Becton, Dickinson and Company (NYSE:BDX) by 2.5% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,475 shares of the medical instruments supplier’s stock after selling 88 shares during the period. Redmond Asset Management LLC’s holdings in Becton, Dickinson and Company were worth $847,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Vanguard Group Inc. increased its holdings in shares of Becton, Dickinson and Company by 2.0% in the third quarter. Vanguard Group Inc. now owns 25,927,519 shares of the medical instruments supplier’s stock valued at $6,703,041,000 after purchasing an additional 516,427 shares in the last quarter. Morgan Stanley boosted its holdings in shares of Becton, Dickinson and Company by 4.5% in the third quarter. Morgan Stanley now owns 10,200,213 shares of the medical instruments supplier’s stock valued at $2,637,062,000 after buying an additional 435,168 shares during the period. Massachusetts Financial Services Co. MA lifted its position in Becton, Dickinson and Company by 11.0% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 5,192,832 shares of the medical instruments supplier’s stock valued at $1,342,503,000 after acquiring an additional 512,566 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of Becton, Dickinson and Company by 9.2% during the third quarter. Ameriprise Financial Inc. now owns 3,630,351 shares of the medical instruments supplier’s stock worth $938,593,000 after buying an additional 304,629 shares in the last quarter. Finally, Clearbridge Investments LLC grew its position in Becton, Dickinson and Company by 0.6% in the fourth quarter. Clearbridge Investments LLC now owns 3,154,438 shares of the medical instruments supplier’s stock valued at $769,147,000 after purchasing an additional 19,200 shares in the last quarter. Institutional investors own 86.97% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BDX. The Goldman Sachs Group began coverage on shares of Becton, Dickinson and Company in a research note on Thursday. They issued a “buy” rating and a $274.00 target price for the company. Barclays raised their price target on Becton, Dickinson and Company from $305.00 to $312.00 and gave the stock an “overweight” rating in a research report on Monday, May 6th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $280.17.

Becton, Dickinson and Company Trading Up 2.3 %

Becton, Dickinson and Company stock traded up $5.19 during trading hours on Friday, hitting $231.97. The stock had a trading volume of 4,733,925 shares, compared to its average volume of 1,428,053. The stock has a market cap of $67.04 billion, a price-to-earnings ratio of 51.09, a P/E/G ratio of 2.03 and a beta of 0.45. The company has a quick ratio of 0.97, a current ratio of 1.41 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $236.38 and its 200-day simple moving average is $237.84. Becton, Dickinson and Company has a one year low of $224.00 and a one year high of $287.32.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Thursday, May 2nd. The medical instruments supplier reported $3.17 earnings per share for the quarter, topping analysts’ consensus estimates of $2.97 by $0.20. The firm had revenue of $5.05 billion for the quarter, compared to analyst estimates of $5.04 billion. Becton, Dickinson and Company had a net margin of 6.76% and a return on equity of 13.90%. The company’s revenue for the quarter was up 4.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.86 EPS. On average, equities analysts predict that Becton, Dickinson and Company will post 13.03 EPS for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 28th. Stockholders of record on Monday, June 10th will be given a dividend of $0.95 per share. The ex-dividend date of this dividend is Monday, June 10th. This represents a $3.80 dividend on an annualized basis and a dividend yield of 1.64%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 83.70%.

Insider Activity at Becton, Dickinson and Company

In other news, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The shares were sold at an average price of $238.29, for a total transaction of $67,197.78. Following the completion of the sale, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Michael David Garrison sold 1,715 shares of the firm’s stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $232.81, for a total transaction of $399,269.15. Following the completion of the sale, the executive vice president now owns 5,381 shares of the company’s stock, valued at approximately $1,252,750.61. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, SVP Thomas J. Spoerel sold 282 shares of the stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $238.29, for a total transaction of $67,197.78. Following the transaction, the senior vice president now directly owns 2,276 shares in the company, valued at $542,348.04. The disclosure for this sale can be found here. Insiders have sold 8,597 shares of company stock worth $2,028,786 over the last ninety days. Insiders own 0.31% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.